- Home
- ARCL vs IPHA Comparison
ARCL vs IPHA Comparison
Compare ARCL & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARCL | IPHA |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.4M | 165.3M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ARCL | IPHA |
|---|---|---|
| Price | $9.99 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 36.4K | ★ 167.1K |
| Earning Date | N/A | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $1.18 |
| 52 Week High | $9.97 | $2.71 |
Technical Indicators
Market Signals| Indicator | ARCL | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 67.38 | 55.87 |
| Support Level | $9.88 | $1.68 |
| Resistance Level | N/A | $2.58 |
| Average True Range (ATR) | 0.01 | 0.14 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 100.00 | 47.80 |
Price Performance
Historical ComparisonAbout ARCL ARC Group Acquisition I Corp Class A Ordinary Shares
ARC Group Acquisition I Corp is a blank check company.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.